KMI APPOINTS DR. RICHARD LEVY VICE PRESIDENT CONSULTING SERVICES
BOSTON, MA, February 4, 2002 — KMI, a subsidiary of PAREXEL International Corporation, (Nasdaq: PRXL) announced the appointment of Dr. Richard V. Levy as Vice President of KMI Consulting Services, effective January 3, 2002. In this capacity, Dr. Levy will direct the KMI Consulting Services Unit consisting of Client Management, Compliance Auditing, Information Technology, Quality Systems, Strategic Compliance, and Validation.
Before joining KMI, Dr. Levy had a distinguished 16-year career with Millipore Corporation. Dr. Levy has expertise in filtration and aseptic processing technology and in product and process validation. In his most recent position at Millipore, he specialized in tactical and strategic marketing and product management of viral clearance products. While at Millipore, Dr. Levy developed validation services and provided guidance in quality systems and regulatory affairs.
“I am pleased to welcome Rich to KMI. Given his reputation and experience, Rich is clearly qualified to provide the level of leadership needed to manage the diverse services offered by KMI,” said Dr. Ronald F. Tetzlaff, KMI President. “Rich is well-suited for this position due to his expertise and experience in microbiology, validation and quality systems, as well as first-hand knowledge of the regulatory requirements in the healthcare industry.”
Dr. Levy is a Board Member of the Parenteral Drug Association (PDA) and was recently elected Treasurer and a member of the PDA Executive Committee. He is also a Board Member of the PDA Foundation for Pharmaceutical Sciences, Inc. of New York. He is a prominent writer and speaker on sterilization filtration and process validation for sterile products. He has authored chapters in more than a dozen books and trade publications. These include: Filtration in the Biopharmaceutical Industry, Validation of Pharmaceutical Processes, Microbiology in Pharmaceutical Manufacturing, Disinfection, Sterilization, and Preservation, and trade publications such as Genetic Engineering News, BioPharm and Pharmaceutical Technology. Dr. Levy has contributed to numerous national and international conferences relating to the biopharmaceutical industry. He has also worked closely with worldwide regulatory agencies such as the Food and Drug Administration (FDA), Medicines Control Agency (MCA), Japanese Ministry of Health, and European Medicines Evaluation Agency (EMEA).
KMI offers a broad range of services and solutions from strategic planning, auditing, and training to the design of standard-compliant quality systems, implementation of information technology solutions, and validation of manufacturing processes. Its consultants include industry experts and former regulatory officials with a wide range of experience in helping clients understand and meet the regulatory challenges of today’s global operations. KMI is headquartered in Waltham; MA with approximately 180 employees operating in10 offices throughout North America and Europe. KMI is a subsidiary of PAREXEL International Corporation, one of the largest contract pharmaceutical outsourcing organizations in the world, providing a broad range of knowledge-based contract research, medical marketing and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries.
This release contains "forward-looking" statements regarding future results and events, including statements regarding expected financial results, future growth and customer demand that involve a number of risks and uncertainties. For this purpose, any statements contained here in that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes", "anticipates", "plans", "expects", "intends" and "appears", and similar expressions are intended to identify forward-looking statements. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the cancellation, revision, or delay of contracts, including those contracts in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; government regulation of certain industries and clients; competition and consolidation within the pharmaceutical industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Form 10-Q for the period ended September 30, 2001, as filed with the Securities and Exchange Commission, which “Risk Factors” discussion is incorporated by reference in this press release. The Company disclaims any duty to update any of the forward-looking statements contained in this press release.